Impax: generic launch was too risky
At opening arguments in the Federal Trade Commission’s tribunal, counsel to the drugmaker Impax argued that the company was not paid to delay generic competition and launching a generic form of Opana ER was too risky when it entered into a 2010 settlement with Opana’s patent-holder.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10